Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT) yesterday and set a price target of $62. The company’s shares closed yesterday at $29.63.
Tanner observed:
“We reiterate our Overweight rating on AIMT stock and we are lowering our PT by $2 to $62. We maintain our belief that AR101 is well- positioned to be the first FDA-approved therapy for treating peanut allergy and view the Phase 3 PALISADE trial data as compelling. If approved, we believe it reasonable that uptake could be moderated by the fact that a new treatment paradigm has been created. However, the unmet medical need will create strong demand for the product, in our view.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 1.9% and a 45.1% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
Aimmune Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $56.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42 and a one-year low of $18.41. Currently, Aimmune Therapeutics has an average volume of 463.5K.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AIMT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
